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ABSTRACT 
Epidermolysis bullosa (EB), a group of heritable blistering disorders, demonstrates extensive 
phenotypic variability due to mutations in as many as 20 distinct genes. There is no cure for this 
devastating group of disorders, however, a number of preclinical developments show promise, 
and some approaches have already reached the stage of early clinical trials. Dystrophic 
Epidermolysis Bullosa Research Association (DEBRA) International, a global coalition of 
national patient organizations advocating on behalf of the patients and families with EB, supports 
research and organizes periodic scientific and clinical meetings on this disease. The latest one, 
EB2017, was held in the context of the European Society for Dermatological Research Meeting 
in Salzburg in September, 2017. This Report summarizes some of the recent research and clinical 
developments which have identified promising avenues towards treatment and perhaps eventual 
cure, with improved quality of life for patients with EB.  
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INTRODUCTION 
Epidermolysis bullosa (EB) is a highly heterogeneous group of skin fragility disorders with 
extensive phenotypic variability and diverse clinical outcomes (for review, see (Fine et al., 
2014). The diagnostic hallmark of this group of diseases is blistering of the skin as a result of 
minor trauma, leading to erosions and non-healing ulcers. In certain subtypes, these findings are 
associated with mutilating scarring and early development of aggressive squamous cell 
carcinomas. In spite of tremendous progress made over the last quarter of a century in 
understanding the molecular genetics and the pathomechanistic pathways in this group of 
disorders, there is no cure as yet.  
DEBRA International, a coalition of national patient organizations, funds research and 
advocates on behalf of the patients and families with EB. Towards this goal, DEBRA 
International organizes periodic research and clinical meetings for investigators working on EB, 
and in related fields, to allow review of the state-of-the-art and to provide a platform for 
exchange of ideas for research prioritization (Bruckner-Tuderman et al., 2013; Uitto et al., 2010; 
Uitto et al., 2016). To reflect the accelerating translation of research into clinical application, 
DEBRA International organized its latest research conference, EB2017, for the first time in 
conjunction with the annual EB-CLINET clinical conference, in Salzburg, Austria (September 
24th-27th, 2017). This meeting was attended by over 250 scientists and clinicians (Figure 1). This 
synopsis summarizes some of the findings reported in this conference.  
 
IDENTIFICATION OF NOVEL GENES AND MUTANT ALLELES WITH CLINICAL 
IMPLICATIONS 
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The heritable forms of EB were initially divided into three broad categories based on the level of 
blistering within the skin as visualized by transmission electron microscopy, viz., simplex (EBS), 
junctional (JEB) and dystrophic (DEB) subtypes (Fine et al., 2014). While this early 
classification was somewhat helpful for prognostication, it was clear that each of these three 
categories represent a spectrum of severity and outcome. This phenotypic variability was 
subsequently shown to reflect mutations in 10 distinct genes expressed within the cutaneous 
basement membrane zone. Subsequently, Kindler syndrome (KS) was proposed to be the fourth 
subtype of EB, and demonstrations of mutations in FERMT1 brought the number of mutated 
genes to 11 (Jobard et al., 2003; Siegel et al., 2003). More recently, a number of genes, primarily 
expressed within the epidermis and largely associated with EBS, brought the total number of 
mutant genes to 18 (Table 1). At the end of 2016, several investigators independently identified 
mutations in a novel gene, KLHL24, in a significant number of patients with EBS (He et al., 
2016; Lee et al., 2017; Lin et al., 2016). Finally, quite recently, a patient with a Kindler 
syndrome-like clinical presentation, including early blistering which subsided with age and 
nephropathy was found to harbor a homozygous splicing mutation in CD151, encoding a 
tetraspanin (TM4) that is expressed at the cutaneous basement membrane zone (Vahidnezhad et 
al., 2017a). These observation, together with previously published cases with similar clinical 
presentations, suggested that the total number of genes harboring mutations in different subtypes 
of EB is at least 20 (Table 1).  
 Identification of mutations in candidate genes in different families with EB was originally 
based on PCR amplification of exons and flanking intronic sequences, followed by Sanger 
sequencing. Considering the large number of candidate genes in EB and the fact that many of 
these genes are large and multi-exonic, this approach has proven to be labor intensive, time 
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consuming and expensive. More recently, a number of next generation sequencing panels 
encompassing EB related genes have been developed, and this relatively inexpensive approach 
has markedly facilitated and streamlined mutation detection in families (Tenedini et al., 2015; 
Vahidnezhad et al., 2017c; Vahidnezhad et al., 2017b). These panels have been supplemented 
with next generation sequencing approaches, including whole exome and whole genome 
sequencing, combined with homozygosity mapping in consanguineous families. These 
approaches have allowed rapid expansion of the mutation databases, and provided tools to 
identify family specific mutations for confirmation of the diagnosis with subcategorization and 
prognostication.  
 
REFINED PHENOTYPE/GENOTYPE CORRELATIONS 
Examination of mutation databases in the context of clinical presentations has allowed 
development of phenotype/genotype correlations, which now form the basis of prognostication, 
in general terms, based on mutations in newborns before phenotypic development is apparent. 
Advanced mutation detection strategies have also identified a number of unusual genetic 
constellations in patients with complex phenotypes, many of which were reported in the 
Symposium. For example, EBS with mottled pigmentation, which has previously been shown to 
result from a specific mutation (p.Pro25Leu) in KRT5, is now shown to also result from 
mutations in the EXPH5 gene (Turcan et al., 2016a). Mutations in BPAG1-e can cause an 
unusual EBS of an intermediate generalized phenotype with a prurigo papules (Turcan et al., 
2017). Large intragenic KRT5 deletions have also been shown to account for some unsolved 
cases of EBS (Has et al., 2017). Mutations in the ITGB4 gene, frequently associated with an 
autosomal recessive form of JEB, can also result in an autosomal dominant form of EB (Turcan 
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et al., 2016b). Unusual genetic alterations in COL7A1 have also been linked to unusual 
phenotypes, as for example, large deletions targeting the triple helical domain of type VII 
collagen that cause acral dominant dystrophic EB (Chmel et al., 2017). Also, a patient initially 
diagnosed with Shabbir syndrome, was found not to have mutations in LAMA3 but in LAMB3 
instead (Vahidnezhad et al., 2017b).  
 
PRECLINICAL DEVELOPMENT OF TREATMENT STRATEGIES 
A spectrum of preclinical approaches has been utlized to develop treatment strategies for EB. 
Therapy approaches aimed at correcting the primary genetic defect at DNA, mRNA or protein 
levels extend from induced pluripotent stem (iPS) cell or keratinocyte-based gene correction and 
protein therapies to antisense oligonucleotides and premature termination codon (PTC) read-
through drugs. Another line of treatment strategies includes disease-modifying, symptom-relief 
therapies, which address inflammatory and fibrotic processes that modify specific EB 
phenotypes. 
 
Preclinical development of iPS cell-based technologies 
At the Symposium, several investigators reported that iPS cells can be derived from EB 
fibroblasts or EB keratinocytes which, in turn, can be re-differentiated after gene correction into 
keratinocytes and fibroblasts. A great advantage of iPS cell-based treatment approaches lies in 
the autologous nature of the cells that are generated and in the lack of immune reactions to 
corresponding tissue grafts. Significant technical advances in production, gene correction/gene 
editing and safety of GMP-quality iPS cells have been reported (Bilousova and Roop, 2014; 
Sebastiano et al., 2014), and examples of quality criteria include minimal cellular heterogeneity 
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and high level of production of the corrected protein, e.g., keratins 5 and 14 in cases of EBS and 
collagen VII in DEB. Furthermore, in order to improve graft quality, refinement of 3D 
organotypic cultures with iPS cell-derived keratinocytes and fibroblasts is being pursued 
(Shinkuma et al., 2016). Finally, inducible pluripotent stem cells (iPSCs) have been established 
from revertant keratinocytes (Tolar et al., 2014; Umegaki-Arao et al., 2014), although clinical 
translation involving these cells has yet to be accomplished. 
 
Protein and mRNA-based approaches 
Prospects of protein therapy using recombinant human collagen VII have been investigated in 
the past few years. Initial observations in a preclinical mouse model suggested that intravenously 
administered collagen VII could reverse the disease phenotype in RDEB (Hou et al., 2015), 
leading to the hypothesis that - in analogy to enzyme deficiencies that can be treated by infusions 
of recombinant enzymes - injections of GMP quality collagen VII might provide a useful 
therapeutic option for individuals with DEB. However, the development of the therapy turned 
out to be more challenging than anticipated, and this project has been taken over by industry 
partners (most recently, http://phoenixtissuerepair.com). It remains to be seen whether this line 
of treatment option can be successfully adapted from mouse models to humans. As an 
alternative, a planned early-stage trial of intradermal injection of recombinant human collagen 
VII, produced following optimization of post translational modifying enzymes  (prolyl-4-
hydroxylase, C-proteinase) to maximize stability and solubility, may offer a future option for 
localized therapy (P. Marinkovich, personal communication). 
Therapeutic approaches targeting gene transcription have been tested mainly with 
COL7A1 as a model. In vitro antisense oligonucleotide treatment of cells with mutant COL7A1 
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genes can lead to skipping of specific exons at RNA level, that when in frame, restores synthesis 
of essentially normal, although slightly shortened collagen VII (Bremer et al., 2016; Turczynski 
et al., 2016). Preclinical in vivo testing has shown that antisense oligonucleotide-based exon 
skipping can promote skin stability by partially functional collagen VII in DEB mice (Bornert et 
al., 2016).  
Another approach targeting gene transcription is based on read-through of premature 
termination codons (PTCs). The premise of this approach is that about 10% of genetic diseases 
are caused by nonsense mutations which introduce PTC and nonsense-mediated mRNA decay  
(Mort et al., 2008). Aminoglycoside antibiotics, such as gentamicins, can induce PTC read-
through. Gentamicins were first tested for their efficacy to induce PTC readthrough for COL7A1 
in vitro, but their effects depend on the local nucleotide microenvironment of the mutations, and 
not all nonsense mutations are amenable to this kind of correction (Cogan et al., 2014; 
Baradaran-Heravi et al., 2017). In addition, the renal and oto- toxicities of aminoglycosides may 
prevent widespread clinical implementation. Nevertheless, a pilot trial assessed topical 
administration of gentamicin to the skin of five patients with RDEB and demonstrated enhanced 
collagen VII synthesis, suggesting that topical application may offer a therapeutic option with 
reduced systemic toxicity of gentamicin (Woodley et al., 2017). Gentamicin preparations are 
mixtures of related molecules, and a minor gentamicin component, gentamicin B1, seems 
promising because of its potency as an inducer of the PTC read-through and its low toxicity 
(Baradaran-Heravi et al., 2017).  Another interesting compound is Amlexanox that induces PTC 
read-through and is thought to inhibit non-sense mediated mRNA decay. Amlexanox has been 
shown to increase mRNA expression and synthesis of full-length collagen VII in RDEB 
fibroblasts and keratinocytes with nonsense mutations (Atanasova et al., 2017). This drug is 
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approved by FDA for other clinical indications, and its toxicity profile and pharmacokinetics 
have been established, thus facilitating its translation to clinical trials. 
 
Preclinical development of symptom-relief therapies 
Symptom-relief therapies are the current focus of EB research with the aim of counteracting 
subjective clinical findings, such as pain and itch as well as skin fibrosis, which greatly impair 
the quality of life of EB patients. Molecular mechanisms responsible for secondary processes are 
now being defined. In EBS, in addition to providing keratinocytes with structural stability 
against mechanical stress, keratin intermediate filaments regulate immune responses by 
controlling expression of IL-1, IL-18 and other cytokines. For example, the cytokine thymic 
stromal lymphopoietin (TSLP) is highly upregulated in EBS and mediates itch in keratin-
deficient mice and patients (Kumar et al., 2016). Keratins and other cytoskeleton-associated 
proteins also contribute to epidermal cell-cell adhesion via spatially and temporarily controlled 
stabilization of desmogleins and their suprastructures, desmosomes (Vielmuth et al., 2017). 
Several other molecules have recently been identified that are altered upon breach of epidermal 
integrity and induce pro-inflammatory signaling (T. Magin, personal communication). Such 
molecules may become therapeutic targets in EBS, and perhaps in other forms of EB. 
One of the most debilitating features of RDEB is progressive soft tissue fibrosis that 
causes joint contractures, deformities of the extremities and strictures at mucosal surfaces, 
particularly in the esophagus. The molecular and cellular mechanisms leading to these 
complications include inflammation and excessive TGF-ß signaling (canonical and non-
canonical). Limiting these processes could substantially improve functionality and quality of life 
of the affected individuals. Losartan, an FDA-/EMA-approved drug, is known to inhibit 
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excessive TGF-ß signaling in some, but not all, fibrotic diseases. In RDEB mice, it efficiently 
reduced inflammation, TGF-ß activity, extracellular matrix accumulation, and progression of 
fibrosis (Nyström et al., 2015). Recent investigations demonstrated that a parallel pathway 
involving signaling through the anti-fibrotic AT-2 and MAS receptors (Passos-Silva et al., 2015) 
can be a target in RDEB. Toward this end, a phase-2 investigator-initiated clinical trial (Reflect 
study, EudraCT-No.: 2015-003670-32) explores safety and tolerability of losartan in children 
with moderate-to-severe RDEB and collects information on its efficacy (D. Kiritsi, personal 
communication). 
Another approach to diminish systemic inflammation and fibrosis focuses on high-
mobility group box 1 (HMGB1)-derived peptide as a potential drug. The HMGB1 factor is 
released from necrotic epithelial cells in RDEB and signals to bone marrow-derived 
mesenchymal stem cells, leading to their migration to circulation and homing to damaged skin 
(Aikawa et al., 2015). In RDEB mice, the HMGB1-derived peptide prevented both skin fibrosis 
and gastrointestinal tract strictures and, importantly, extended the life-span of the mice 
significantly (K. Tamai, personal communication).  
Collectively, preclinical development of biologically valid treatments shows encouraging 
promise for future therapies. In particular, remodeling of the dermal matrix by fibroblasts in the 
absence of collagen VII in RDEB results in key changes in gene-expression profiles and there is 
increasing evidence that this drives the development of aggressive SCC (Martins et al., 2016). 
Notably, stromal modulators of TGF-β activity that, in turn, drive metastasis, angiogenesis and 
activation of fibroblasts (Costanza et al., 2017), are likely targets for drug development to 
combat SCC in EB.  
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EARLY CLINICAL TRIALS IN EB   
Based on the progress made in understanding the genetic basis and pathomechanistic details of 
EB leading to skin fragility and extensive exploration of treatment opportunities at the preclinical 
level, the pipeline for clinical trials in EB has opened. In fact, 61 clinical trials involving EB 
patients are currently registered in clinical.trials.gov (USA), and 16 of these were registered in 
2016-2017, reflecting acceleration of clinical trial activity in this disease (H. Rischel, personal 
communication). Additional clinical trials and observational studies registered in the European 
Union may be found at Eudract CT register (https://eudract.ema.europa.eu/results-web/), and 
worldwide at the World Health Organization register (http://www.who.int/ictrp/en/). Thus, 
diverse approaches to develop treatments that improve quality of life and provide eventual cures 
for EB patients are being pursued. 
 
Bone marrow transplantation 
In 2010, the results of an early clinical trial of whole bone marrow transplantation (BMT) in six 
children with recessive DEB (RDEB) were reported (Wagner et al., 2010). That study described 
clinical improvements in all subjects and five of the six showed increased collagen VII 
deposition at the dermal-epidermal junction. No individual was cured after BMT, but several 
showed a marked reduction in blister formation and substantial improvement in quality of life. 
However, toxicity relating to myeloablative conditioning was a concern because of high 
morbidity and mortality. Seven years on, this EB Symposium provided an opportunity to reflect 
on the BMT experience and its value for clinical application in EB. Globally, but mainly due to 
the considerable experience from the University of Minnesota, more than 40 children with either 
RDEB or JEB have now undergone BMT. Although detailed results of the clinical experiences 
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of the subsequent clinical trials have yet to be published, a number of lessons are emerging. 
Notably, (1) beneficial and sustained clinical responses, but not cures, continue to be noted in 
some, but not all, children with RDEB undergoing BMT; (2) mortality rates with revised 
conditioning protocols have decreased and are now ~15%; (3) some RDEB children show 
positive clinical improvement even in the absence of an increase in collagen VII in their skin; (4) 
experience of BMT in JEB is limited but, with occasional exceptions, BMT does not appear to 
have therapeutic benefit in this type of EB (J. Tolar, personal communication; (Hammersen et 
al., 2016).  
For families with children who have RDEB, many personal dilemmas remain: BMT is an 
experimental therapy and is being performed as part of a number of clinical trials; it should not 
be considered to be an approved therapy. The mortality risk and the uncertainty of the degree and 
mechanism of clinical response need to be weighed against the present status of translational 
research in RDEB, which is that BMT is currently the only treatment approach that has 
demonstrated a systemic impact on what is a systemic disease. There is clearly a need for the 
data from the extended clinical trials to be published as soon as possible, with a view to 
developing recommendations and caveats for use of BMT for EB. 
 
Cell therapy 
Previously, randomized double-blind clinical trials of intradermal injections of allogeneic 
fibroblasts into RDEB skin showed varying results on the extent or rate of re-epithelization of 
chronic erosions (Venugopal et al., 2013; Petrof et al., 2013). Nevertheless, a universal adverse 
finding was the considerable pain that results from injecting cells into often scarred skin. This 
type of local cell therapy has, therefore, now focused on delivering COL7A1 gene therapy in 
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autologous fibroblasts to both intact skin and RDEB wounds (clinical trials.gov identifiers 
NCT02493816 and NCT02810951). In contrast, allogeneic cell therapy has progressed to 
systemic testing. An early phase clinical trial of intravenously administered allogeneic 
mesenchymal stromal cells (MSCs) in 10 children with RDEB showed improvements in wound 
healing, as well as reduction in pain and itch, and a positive impact on quality of life (Petrof et 
al., 2015). A similar study in 10 adults with RDEB is currently being evaluated for safety and 
early efficacy (clinical trials.gov identifier NCT02323789). Clinical benefits appear to be 
sustained for up to 9 months, with further improvements after additional cell infusions, raising 
the possibility of repeated infusions of this form of mesenchymal stromal cell therapy having 
potential clinical utility. The likely benefits relate to the anti-inflammatory effects of the cells as 
skin biopsies have not shown any increase in collagen VII or new anchoring fibrils in the treated 
patients’ skin. Indeed, additional preclinical work has shown that this type of systemic delivery 
cannot deliver adequate cell numbers needed to restore collagen VII expression at the cutaneous 
basement membrane zone (Kuhl et al., 2015).   
 
Gene therapy 
Since the initial report of successful gene therapy based on grafting of ex-vivo corrected 
keratinocytes to the patient’s skin in an individual with JEB, published in 2006 (Mavilio et al., 
2006), there have been few public reports of progress using this treatment for EB. In December 
2016, however, the results of a single center clinical trial of ex-vivo cultures of RDEB 
keratinocytes, transduced with a retroviral vector containing full-length COL7A1 cDNA, and re-
grafted back onto the patient’s wounds as epidermal sheets, were reported (Siprashvili et al., 
2016). There was evidence of wound healing and collagen VII expression in most samples, 
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although the clinical response was variable and generally declined over the following 12 months. 
However, the procedure was deemed safe and the data have provided a basis for expansion of 
this approach to further trials in more people with RDEB. A similar approach has been taken to 
correct the defect in a JEB patient with chronic non-healing ulcers in which grafting of the gene-
corrected keratinocytes demonstrated remarkable healing (Bauer et al., 2017). One potential 
criticism of ex-vivo/keratinocyte gene therapy approaches has often been that they can only be 
applied to a limited areas of skin, and thus it would be unlikely to have much impact on overall 
health and quality of life. However, this notion has recently been dispelled in an extraordinary 
account of the use of ex-vivo holoclone stem cell-derived keratinocyte gene therapy to replace 
over 90% of the skin of a 7-year-old boy with generalized intermediate JEB caused by LAMB3 
mutations (Hirsch et al., 2017). The cost and general applicability of the approach remain 
controversial, but there can be no denying the incredible transformation in the life of the boy 
who was treated. 
 
Novel Topical Treatments 
Topical therapies, with easy applicability and low toxicity, remain an attractive avenue of 
translational research in EB, even if the therapeutic mechanisms underpinning such treatments 
are not fully known. A number of products have been, or are being, tested in proof-of-concept or 
later phase early clinical trials. For example, a betulin-rich triterpene extract from birch bark 
(Oleogel-S10, Birken AG) has been assessed in an open, blindly evaluated, controlled, 
prospective phase-2 pilot trial in wounds in individuals with DEB (EudraCT number 2010-
019945-24). In evaluating 12 wound pairs in 10 subjects, there was a trend towards accelerated 
wound healing with the intervention but statistical significance was not demonstrable 
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(Schwieger-Briel et al., 2017). A larger study to assess the reproduciblity of these preliminary 
observations is ongoing (J. Kern, personal communication). 
 The importance of controlled clinical trials in developing topical treatments for EB is 
emphasized by recent studies attempting to develop 6% allantoin as a new drug enhancing 
wound healing in EB (SD101; Amicus). Allantoin, has been previously shown to enhance 
epidermal wound healing in model systems, and early observations in a limited number of EB 
patients suggested beneficial effects. A large clinical trial involving more than 160 patients with 
different forms of EB indeed demonstrated improvement in the treated patients, however, the 
vehicle treated controls did equally well, probably reflecting the meticulous daily care of the 
patients enrolled in the trial. Thus, the study failed to demonstrate definitive improvement 
attributable to allantoin, but ongoing subgroup analysis may identify forms of EB and certain age 
groups that might benefit for this application.  
DEBRA has, as a patient organization, supported EB research for over 30 years, from 
studies into the underlying pathology of  EB through to proof-of-principle therapeutic concept 
studies and early-stage clinical trials. More recently, DEBRA has initiated studies, such as 
Prospective Epidermolysis Bullosa Longitudinat Evaluaton Study (PEBLES), to document the 
natural history of RDEB towards identification and validation of clinically appropriate 
parameters against which therapies may be evaluated in clinical trials. In recognition of the 
essential role of the biopharma industry as partners in developing therapies, DEBRA 
International organized an ‘Industry Partnering Panel’ workshop at EB2017, to consider how 
DEBRA can assist in overcoming common barriers faced by companies engaging in EB clinical 
trials. A consortium approach, engaging with industry and other stakeholders, is now in 
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development to address these challenges, and to expedite creation and delivery of clinical 
treatments. 
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FIGURE LEGEND 
 
Figure 1. Some of the participants in the joint DEBRA International EB2017 Research 
Symposium and EB-CLINET Clinical Conference held in Salzburg, September 24-27, 2017 
(Photo courtesy of Dr. Rudolf Hametner). 
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Table 1. Classification, Phenotypic Spectrum, and Molecular Heterogeneity of Epidermolysis Bullosa 
Associated Phenotypes and Other Comments No. of  
Reported  
Mutationsa) 
Inheritance Protein Chromosomal  
Location 
Mutated 
Genes 
Type of EB 
Epidermolysis bullosa, lethal acantholytic 265b) AR Desmoplakin 6p24.3 DSP   EBS 
Ectodermal dysplasia/skin fragility syndrome 16 AR Plakophilin1 1q32.1            PKP1 
Skin fragility, palmoplantar keratoderma, and woolly hair, with or without 
cardiomyopathy 
40c) AR Plakoglobin 17q21.2     JUP 
75% of all EBS cases; 14 cases of AR EBS-K14 have been reported 151d) AD Keratin 5 12q13.13       KRT5 
114e) AD, AR Keratin 14 17q21.2       KRT14 
Form of EBS; EB with pyloric atresia, EB with muscular dystrophy; Rare AD 
EBS-Ogna 
92 AR (AD) Plectin 8q24.3       PLEC1 
 6 AR BPAG1 6p12.1       DST 
 8 AR Exophilin 5 17q25.1       EXPH5 
Acral peeling skin syndrome 26 AR Transglutaminase 5 10q24.3-q25.1    TGM5 
EBS, generalized, with scarring and hair loss 5 AD Kelch-like protein in 24 3q27.1 KLHL24 
9% of all JEB cases 48 AR Laminin-332 18q11.2       LAMA3 JEB 
70 % of all JEB cases 112 AR 1q32.2       LAMB3 
9% of all JEB cases 39 AR 1q25.3       LAMC2 
12% of all JEB cases 99f) AR Collagen XVII 10q24.3-q25.1    COL17A1 
A few reported cases 8 AR α6β4 integrin 2q31.1     ITGA6 
AD mode of inheritance reported in one study 95 AR (AD) 17q25.1       ITGB4 
Four cases of EB reported with congenital nephrotic syndrome and interstitial 
lung disease  
11 AR Integrin α3 subunit 17q21.33       ITGA3 
100% of all DEB cases 773 AR, AD Collagen VII 3p21.31      COL7A1 DEB 
100% of all KS cases 78 AR Kindlin-1 20p12.3       FERMT1 KS 
EB with nephropathy 2 AR Tetraspanin CD151 11p15.5 CD151 KS-like 
a)The numbers represent the total number of distinct disease-associated mutations according to The Human Gene Mutation Database (www.hgmd.cf.ac.uk) as of 11/22/2017. Mutations in KLHL24 not yet 
available on this database, were gathered from the three existing reports of KLHL24-associated EB, as summarized by Has, 2017 (Has, 2017). 
b)In addition to EBS, mutations in DSP are related to following diseases: Arrhythmogenic right ventricular dysplasia 8 (OMIM:607450); Cardiomyopathy, dilated, with woolly hair and keratoderma 
(OMIM:605676); Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis (OMIM: 615821); Epidermolysis bullosa, lethal acantholytic (OMIM:609638); Keratosis palmoplantaris striata II 
(OMIM:612908); Skin fragility-woolly hair syndrome (OMIM:607655). 
c)JUP mutations can cause AR Naxos disease (OMIM:601214); AD mutations can lead to arrhythmogenic right ventricular dysplasia 12 (OMIM:611525). 
d)KRT5 mutations are related to EBS and Dowling-Degos disease.  
e)Mutations in KRT14 cause different types of EBS (including with mottled pigmentation), as well as dermatopathia pigmentosa reticularis and Naegeli-Franceschetti-Jadassohn syndrome. 
f)Mutations in COL17A1 cause DEB and inherited epithelial recurrent erosion dystrophy (ERED)-like disease with eye manifestations only. 
AR, autosomal recessive; AD, autosomal dominant 
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